DDW: Certain Proteins Predict Metabolic Dysfunction-Associated Steatotic Liver Disease
By Elana Gotkine HealthDay Reporter
FRIDAY, April 25, 2025 -- Five proteins are significant predictors of metabolic dysfunction-associated steatotic liver disease (MASLD), according to a study presented at the 2025 Digestive Disease Week, held from May 3 to 6 in San Diego.
Shiyi Yu, M.D., from the Guangdong Provincial People's Hospital in Guangzhou, China, and colleagues analyzed proteomics data from 52,952 U.K. Biobank participants without baseline MASLD to identify accurate long-term biomarkers and develop predictive models for MASLD.
Five of the 2,737 proteins analyzed emerged as robust predictive biomarkers for MASLD incidence within five years: CDHR2 (area under the curve [AUC], 0.825), FUOM (AUC, 0.815), KRT18 (AUC, 0.810), ACY1 (AUC, 0.803), and GGT1 (AUC, 0.797). The researchers observed significant deviations in plasma concentrations of these proteins up to 16 years before MASLD onset. A markedly increased risk for MASLD was seen for participants with higher baseline levels of these proteins (hazard ratios, 7.05 to 9.81). The combination of five proteins showed predictive ability for MASLD up to 16 years, with accuracy varying across time frames: AUCs, 0.857, 0.775, 0.739, and 0.758 for five years, 10 years, more than 10 years, and all time, respectively. When combined with clinical predictors, the predictive performance was further enhanced: AUCs, 0.894, 0.840, 0.807, and 0.822 for five years, 10 years, more than 10 years, and all time, respectively. Cohorts from different regions showed minimal variation in AUC, supporting the robustness of the model.
"The field urgently needs effective biomarkers and predictive models, and our research shows that plasma proteins offer novel potential strategies for early prediction and intervention," Yu said in a statement.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted April 2025
Read this next
Dapagliflozin Beneficial for Improving MASH Without Worsening Fibrosis
FRIDAY, June 6, 2025 -- For patients with metabolic dysfunction-associated steatohepatitis (MASH), treatment with dapagliflozin is beneficial for improvement of MASH without...
Metabolic Dysfunction-Linked Steatotic Liver Disease Tied to Increased Preterm Birth Risk
TUESDAY, May 20, 2025 -- Metabolic dysfunction-associated steatotic liver disease (MASLD) in pregnant women is a risk factor for preterm birth, according to a study published...
Study IDs Trends in 2015 to 2023 Mortality for Chronic Liver Disease
THURSDAY, May 8, 2025 -- Distinct trends were seen in etiology-based mortality with chronic liver disease (CLD) before, during, and after the COVID-19 pandemic, according to a...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.